Richards Group (RIC) Q4 2025 earnings summary

Executive summary

• Achieved revenue growth of 5.5% to $430.2M, driven by acquisitions despite organic declines in healthcare and packaging segments.

• Completed three major healthcare acquisitions, including entry into international OEM markets.

• Converted from an income trust to a corporation, with shares now trading on the TSX.

• Healthcare segment posted strong revenue and margin growth, while packaging faced challenges in the US food & beverage category.

Financial highlights

• Revenue: $430.2M (up $22.4M, +5.5% year-over-year).

• Adjusted EBITDAAL: $54.8M (down $2.1M, -3.7% year-over-year).

• Net income: $16.4M (down $19.4M year-over-year), EPS $1.44 (down from $2.99).

• Gross margin: $180.2M, 41.9% of revenue (up from 39.7%).

• Free cash flow: $34.9M; working capital: $89M.

• Debt/EBITDAAL ratio: 1.0x; total debt $58.7M.

Outlook and guidance

• Management expects to sustain monthly dividends and meet capital needs through 2026.

• Healthcare revenue started strong in 2026; packaging demand softened, with focus shifting to margin over volume.

• Maintenance capital for 2026 projected at $5.0M, with continued investment in IT and OEM development.